Linked Life Data

11341746

Source:http://linkedlifedata.com/resource/pubmed/id/11341746

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-5-8
pubmed:abstractText
The changes in serum levels of serum amyloid A protein were studied in 67 patients suffering from colorectal carcinoma and compared to three other major acute phase proteins: C-reactive protein, alpha1-antichymotrypsin and alpha1-acid glycoprotein. Although the presence of colorectal carcinoma caused an increase in serum levels of all the acute phase reactants studied, serum amyloid A protein showed the most powerful reaction in pre-operative disease stage, with the mean value of 330 mg/l (range 7-2506 mg/l) as compared to the normal values of <1.2 mg/l obtained in 30 healthy adults. The mean serum amyloid A protein concentration increased to 487 mg/l after surgery, declining during the post-operative clinical course until the sixth chemotherapy cycle (from 167 mg/l to 64 mg/l), but never returned to the normal range. In the later chemotherapy cycles, mean serum amyloid A protein increased to 163 mg/l, probably as a result of the disease relapse. According to the statistical relations among exact confidence intervals for proportions, serum amyloid A protein showed the best specificity for colorectal carcinoma of all the acute phase proteins studied (83-100%) and also a sensitivity of 100%. We concluded that serum amyloid A protein seems to be a reliable parameter, which could be recommended for clinical routine as a non-specific tumour marker for colorectal carcinoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1434-6621
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
129-33
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Serum amyloid A protein (SAA) in colorectal carcinoma.
pubmed:affiliation
PLIVA d.d., Research & Development, Pharmacology & Toxicology, Zagreb, Croatia. ines.glojnaric@pliva.hr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't